USPTO serial 88667306
PARVULET
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 16, 2021
- Examiner
- MCDORMAN, ROGER THOMAS
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with PARVULET?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,046*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shawn Duckworth
Shawn Duckworth Dennemeyer & Associates, LLC230 W. Monroe St.Suite 2100Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations for the treatment of pain relief and pain management, fever management, shock, hemorrhage and bleeding, pre- and post-operative complications in the nature of hemorrhage, bleeding, thrombosis, emboli, stroke, apoplexy, lesions, respiratory and circulatory crises and dysfunctions, cognitive dysfunctions, fibrosis, infections, inflammation, fever and sepsis, and traumas and emergencies, namely, fractures, abrasions, burns, psychological and immunological shock, poisons and pollutions, animal bites or stings, fever, respiratory and cardiovascular shock, crises and dysfunctions, and hemorrhage, bleeding, thrombosis, emboli, stroke, apoplexy, lesions and cognitive dysfunctions, and physical and psychological substance dependence, namely, drug and alcohol dependence, drug tolerance, withdrawal symptoms, convulsions, Alzheimer disease, dementias, Parkinson's disease, insufficient saliva and inability to swallow, allergy/immunology disorders, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases in the nature of flu, AIDS/HIV, anthrax, plague, cholera, biological infections, and prion exposure, diseases and afflictions of the gastroenterological system, disbiosys, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, genitourinary diseases and afflictions, premature labor, poison exposure, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions on the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions; dietetic food adapted for medical use; diagnostic preparations for medical and veterinary use; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; synthetic peptides for pharmaceutical purposes, namely, for the treatment of illnesses characterized by lack of such peptides and analogues thereof; vitamins; biologics being biopharmaceuticals and biologically active substances for the treatment of exocrine pancreatic insufficiency, cystic fibrosis; pharmaceutical and nutraceuticals preparations, namely, a drug delivery system comprising polymer-based oral tablets, oral powder, oral liquids, oral suspensions, oral gels, and oral emulsions for the immediate or controlled, extended, delayed, pulsatile, local release release of a wide variety of therapeutic agents within a certain time after ingestion; oral powder for reconstitution, namely for immediate or controlled, extended, delayed, pulsatile, local release of a wide variety of therapeutic agents within a certain time after ingestion; medical gel; medicated candy; medicated chewing gum; medicated lollipops; sweets for medicinal purposes, namely, sweets containing pharmaceutical and medical substances and compounds and nutraceuticals; drug delivery systems comprising polymer-based oral tablets, oral powder for immediate or controlled, extended, delayed, pulsatile, local release of a wide variety of therapeutic agents; drug delivery agents for various pharmaceuticals, drugs, medicines, compounds and substances in the form of liquids, gels, grains, powder, emulsions; drug delivery powder for reconstitution in water before administration | ACTIVE | — |
| 010 | Surgical, medical, dental and veterinary apparatus and instruments, namely, drug delivery apparatus and instruments in the form of containers in the nature of blister packs and sachets for various pharmaceuticals, drugs, medicines, compounds and substances sold without medication; spoons, cups and syringes for administering pharmaceutical substances and medicines; drug delivery systems, namely, drug delivery patches sold without medication, implantable drug delivery ports, intravenous bags sold empty for intravenous therapy | ACTIVE | — |
| 040 | Treatment of materials, namely, milling, mixing, grinding, liquefying, pulverizing, melting and extrusion of medical and pharmaceutical substances, compounds and materials for others | ACTIVE | — |
| 042 | Scientific research; technology consultation in the field of scientific research; design for others in the fields of pain relief and pain management, fever management, inflammation, pharmaceutical drug and medicine development, development of medicines and medicine goods and packaging in the fields of traumas and emergencies, addictions, aging, allergy/immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, disbiosys diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical- and gynecological field, occupational diseases and afflictions, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear-nose and throat, diseases and afflictions on the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions, veterinary preparations for the treatment of bovine, sheep, horses, pigs, poultry, ostrich, rodents, dogs, cats, camels, donkeys, elephants; chemical, biochemical, biological and bacteriological research and analysis; pharmaceutical drug and medicine development services; design for others in the field of drugs and medicines; development of pharmaceutical preparations and medicines; professional consultancy pertaining to pharmacology, namely, biotechnical and biomedical and medical and pharmaceutical substances, preparations and compounds; professional consultancy in the field of research, design and development of medicine and the dispensing of pharmaceutical preparations; pharmaceutical drug development services comprised of scientific, industrial, technological, bio technical, pharmaceutical, biomedical and clinical research in the field of drugs and drug candidates and biologics; medical and scientific research, namely, conducting clinical trials of new drug candidates; consultation in the field of scientific research pertaining to chemical, pharmaceutical and medical goods; design for others in the field of medical packaging and equipment; development of pharmaceutical preparations and medicines with improved compliance and acceptability by the patients; consultation in the field of biotechnological and biomedical scientific research; biochemical and molecular biological analyses; in vitro and in vivo preclinical tests and clinical tests of drug candidates and potential drugs; consultancy and research regarding pharmaceuticals in gel-like, gelling and viscous liquid dosage forms; consultancy and research pertaining to pharmacology in the nature of alternative drugs for the young, elderly and those with difficulties swallowing solid dosage forms such as pills and tablets; development of in vitro and in vivo preclinical tests of drug candidates and potential drugs and biologics; biochemical and molecular biological analyses of pharmaceuticals and nutraceuticals preparations to ensure efficacy and safety; scientific, industrial, technological and biotechnological analysis in the field of pharmaceutical and veterinary drug and medicine analysis, analysis of drug delivery apparatus and containers, analysis of synthetic peptides or other biologics analogues for pharmaceutical purposes, analysis of peptide substrates, analysis for the purpose of detecting various toxins, analysis of drug candidates and potential drugs; preparation of materials for promotional documents and campaigns | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ADARE PHARMACEUTICALS, INC
- Other trademarks owned by ADARE PHARMACEUTICALS, INC
- Other trademarks owned by ADARE PHARMACEUTICALS, INC
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named PARVULET
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 16, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 20, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 20, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 20, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 20, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 20, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 16, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 1, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 1, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 11, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 26, 2020 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Oct 23, 2020 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Oct 19, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 17, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 16, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 16, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 23, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 23, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 23, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 2, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 2, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jun 22, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 3, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 3, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 3, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 30, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 30, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 28, 2019 | NWAP | NEW APPLICATION ENTERED | — |